3Q26 Earnings: Upcoming Catalysts and Model Update

研报英文原文证据摘录

3Q26 Earnings: Upcoming Catalysts and Model Update

EQUITY RESEARCH TEAM

Research Management Emerging Oncology Cardiovascular, Endocrine

Disorders & Infectious Disease

Jim Kelly Jonathan Chang, Ph.D., CFA

Director of Equity Research (617) 918-4015 Roanna Ruiz, Ph.D.

(212) 277-6096 jonathan.chang@leerink.com (212) 277-6144

jim.kelly@leerink.com roanna.ruiz@leerink.com Albert Agustinus, Ph.D.

Christian Clark (617) 918-4039 Michael Ahn, Ph.D.

Associate Director of Research albert.agustinus@leerink.com (212) 277-6169

(212) 277-6117 michael.ahn@leerink.com Yiwen Zhang Ph.D.

christian.clark@leerink.com (617) 918-4014

Life Science Tools & DiagnosticsMichelle Ko yiwen.zhang@leerink.com

Business Manager

(212) 277-6021 Genetic Medicine Puneet Souda (212) 277-6091

michelle.ko@leerink.com puneet.souda@leerink.com Mani Foroohar, M.D.

Diversified Biopharmaceuticals (212) 277-6089 Carlos Penikis, CFA

mani.foroohar@leerink.com (212) 404-7225

David Risinger, CFA Lili Nsongo, Ph.D. carlos.penikis@leerink.com

(212) 404-4539 (212) 277-6229 Philip S. Song

david.risinger@leerink.com lili.nsongo@leerink.com (212) 404-4587

Omari Baruti, Ph.D. Valentine Andreu, Ph.D. philip.song@leerink.com

(212) 277-6218 (212) 277-6245 Michael Sonntag

omari.baruti@leerink.com valentine.andreu@leerink.com (212) 277-6048

Jason Zhuang Ryan McElroy, CFA michael.sonntag@leerink.com

(212) 404-4552 (212) 277-6175 Medical Devices and TechnologyJason.zhuang@leerink.com ryan.mcelroy@leerink.com

Targeted Oncology Mike Kratky, CFA Immunology & Metabolism (212) 277-6111

Andrew Berens, M.D. Thomas J. Smith mike.kratky@leerink.com

(212) 277-6108 (212) 277-6069 Brett Gasaway

andrew.berens@leerink.com thomas.smith@leerink.com (212) 404-4588

Amanda Acosta-Ruiz, Ph.D. Nat Charoensook, Ph.D., CFA brett.gasaway@leerink.com